<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728663</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 08/07</org_study_id>
    <secondary_id>SWS-SAKK-08-07</secondary_id>
    <secondary_id>MERCK-SAKK-0807</secondary_id>
    <secondary_id>SANOFI-AVENTIS-SWS-SAKK-0807</secondary_id>
    <secondary_id>CDR0000599858</secondary_id>
    <nct_id>NCT00728663</nct_id>
  </id_info>
  <brief_title>Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
      them or carry tumor-killing substances to them. Cetuximab may also stop the growth of
      prostate cancer by blocking blood flow to the tumor. Giving docetaxel together with cetuximab
      may kill more tumor cells.

      PURPOSE: This phase II trial is studying the side effects of giving docetaxel together with
      cetuximab and to see how well it works in treating patients with metastatic prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To assess the efficacy and safety of docetaxel and cetuximab in patients with
           docetaxel-resistant hormone-refractory prostate cancer

      OUTLINE: This is a multicenter study.

      Patients receive cetuximab IV once weekly and docetaxel IV on day 1 (3-week courses) or on
      days 1, 8, and 15 (4-week courses). Treatment repeats every 3 weeks for up to 8 courses or
      every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed at 4 weeks and then every 3 months
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>All AEs will be assessed according to NCI CTCAE v3.0.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) response (30% and 50% PSA response)</measure>
    <time_frame>is defined as a decrease in PSA level of at least 50% (compared to baseline PSA) confirmed after 3-4 weeks (according to the PSA working group consensus criteria)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment of measurable disease according to RECIST criteria</measure>
    <time_frame>after 12 weeks of treatment, or earlier if clinically indicated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment of bone lesions</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>calculated from registration until death.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm: Cetuximab and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle
--- for max. 24 weeks or until progression or unacceptable toxicity ---</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8
--- for max. 24 weeks or until progression or unacceptable toxicity ---</description>
    <arm_group_label>Arm: Cetuximab and Docetaxel</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle
--- for max. 24 weeks or until progression or unacceptable toxicity ---</description>
    <arm_group_label>Arm: Cetuximab and Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Metastatic adenocarcinoma of the prostate

          -  Must have received one of the following treatment schedules for at least 12 weeks
             prior to study therapy:

               -  Docetaxel 75 mg/m^2 on day 1 of a 21-day course

               -  Docetaxel 35 mg/m^2 on days 1, 8, and 15 of a 28-day course

          -  Must demonstrate hormone-resistance, defined as tumor progression after orchiectomy or
             during treatment with hormonal agents (i.e., luteinizing hormone-releasing hormone
             [LHRH] agonists)

          -  Elevated prostate-specific antigen (PSA) &gt; 2 ng/mL and PSA progression after at least
             12 weeks treatment with docetaxel/prednisone, within 90 days after discontinuation of
             docetaxel/prednisone treatment, under continued hormonal treatment (i.e., LHRH
             agonists or orchiectomy), and meets 1 of the following criteria for PSA progression:

               -  PSA increase of ≥ 25% above the nadir

               -  PSA increase of ≥ 25% above the baseline if no decrease has been observed

                    -  The increase is a minimum of 2 ng/mL, and it is confirmed 1 week later

          -  No presence or history of CNS metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Neutrophils ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT ≤ 2.5 times ULN

          -  Creatinine clearance ≥ 30 mL/min

          -  Patient compliance and geographic proximity allow proper staging and follow-up

          -  Peripheral neuropathy &lt; grade 2

          -  No prior malignancy within the past 5 years with the exception of localized
             nonmelanoma skin cancer or Ta or Tis bladder cancer

          -  No known hypersensitivity to trial drugs or any of their components

          -  No serious underlying medical condition that, in the judgment of the investigator,
             would preclude the patient's ability to participate in the trial (e.g., active
             autoimmune disease, uncontrolled or acute severe infection, or uncontrolled diabetes)

          -  No psychiatric disorder precluding understanding of information on trial related
             topics, giving informed consent, or interfering with oral drug intake compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 2 weeks since prior radiotherapy

          -  More than 6 weeks since prior treatment with antiandrogens (i.e., flutamide or
             bicalutamide)

          -  No prior chemotherapy other than docetaxel for metastatic prostate cancer

          -  No other concurrent experimental drugs or other anticancer therapy

               -  Concurrent bisphosphonates and LHRH agonists allowed provided these medications
                  started at least 2 months prior to study therapy

          -  No treatment in a clinical trial within the past 30 days

          -  No prior treatment with drugs interacting with epidermal growth factor receptor (i.e.,
             cetuximab, panitumumab, gefitinib, erlotinib hydrochloride, or multi-tyrosine kinase
             inhibitors)

          -  No concurrent drugs that, according to the Swissmedic-approved product information,
             are contraindicated for use with the trial drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Cathomas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger von Moos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silke Gillessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AndreasKlinik Cham Zug</name>
      <address>
        <city>Cham</city>
        <zip>CH-6330</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital, Luzerne</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Cathomas R, Rothermundt C, von Moos R, et al.: Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07). [Abstract] J Clin Oncol 28 (Suppl 15): A-4666 , 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12.</citation>
    <PMID>22977195</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

